• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    TMC Expands Executive Team

    Peli BioThermal Opens Cold Chain Network Station in Southern California
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Purolite Expands Bioprocessing Production Capacity with New U.S. Facility
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Biocair Partners with TrakCel to Improve Visibility in the Supply Chain

    SpectronRx, RLS Partner to Boost Radiopharmaceutical Pipeline and Supply Chain

    Serialization and the War on Counterfeit Drugs

    Traceability & 2D Barcodes
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Almac Group Global Workforce Hits 7,000 Employees

    Amarna Therapeutics Names Henk Streefkerk CEO

    Trinity Life Sciences Names Leslie Orne CEO
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Regulatory Affairs: Accelerating Drug Development Timelines

    Berkshire Sterile Secures Over $230,000 in Training Grants

    Purification – A Bottleneck for Large-Scale Manufacturing of Oligonucleotide API?

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    Federal Equipment Company

    Lannett CDMO

    Alcami

    U.S. Pharmacopeia (USP)
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    Federal Equipment Company

    Lannett CDMO

    Alcami

    U.S. Pharmacopeia (USP)
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    FDA Inspection Preparation

    How to get ready for an FDA inspection – important things to know when preparing for an FDA inspection.

    FDA Inspection Preparation
    Tamil Arasu, Principal Consultant, Lachman Consultants04.04.23
    When an FDA investigator walks into your facility informing that they are going to conduct an inspection, a tense moment may arise even at the most cGMP (Current Good Manufacturing Practices) compliant facility. Paging the employees to inform them of the presence of FDA at the facility is a common occurrence so that they are prepared to face the investigator or a team of investigators. However, being prepared all the time for such a moment can bring the anxiety down to some extent. FDA publishes its Investigations Operations Manual (IOM)1 annually and Chapter 5 represents “Establishment Inspections” which provides complete details for the investigators to follow during an FDA inspection. In this article, we are highlighting the types of FDA inspections that are conducted at a pharmaceutical facility focusing on drugs. Generally, the Office of Regulatory Affairs (ORA) conducts the inspections, however, it is not uncommon for the Center for Drug Evaluation and Research (CDER) personnel to join or independently conduct FDA inspections, particularly during Pre-approval Inspections.

    1. Types of FDA Inspections

    FDA conducts four types of inspections in a pharmaceutical facility to help protect consumers from unsafe products. They are as follows:

    Surveillance Inspections. These cGMP inspections are conducted on a routine periodical basis of a regulated facility. These are also called cGMP or routine inspections and cover both domestic and international facilities. These inspections cover the pharmaceutical systems, namely, Quality, Facilities & Equipment, Materials, Production, Packaging & Labeling and Laboratory Control.

    Pre-approval Inspections (PAI). These inspections are conducted after a company submits an application to FDA to market a new product. These inspections are performed to contribute to FDA’s assurance that a manufacturing facility named in a drug application is capable of manufacturing a drug, and that submitted data are accurate and complete. There are three primary inspection objectives of a PAI, which are, Readiness for Commercial Manufacturing, Conformance to Application and Data Integrity audit.

    Post-approval Inspections. These inspections are conducted for products marketed under a recently approved application. The main objectives of these inspections are to assure that any changes in manufacturing and process control are in compliance with cGMP regulations and to assure that all changes are documented in supplemental applications or annual reports. These assignments are issued by CDER based on recommendations and risk.

    For Cause or Directed Inspections. These inspections are harder to prepare for and the investigator may have a specific assignment that is not publicly available. Requests for for-cause inspections can be initiated by Office of Regulatory Affairs (ORA), CDER sub-offices, namely, Office of Process and Facilities (OPF), Office of Surveillance (OS), or Office of Compliance (OC). Once the initiating office determines a for-cause inspection is warranted, the office prepares an assignment that sets forth the areas of required coverage which may or may not include surveillance program coverage.

    2. Difference Between Domestic and International Inspections

    The main difference between domestic and international inspections is that FDA will issue a Form FDA 482 Notice of Inspection to a domestic firm but will not issue to an international firm. The other major difference normally observed is the time period of the inspection. A domestic inspection may easily extend beyond a week, but an international inspection normally will last for five days but may extend in case of a sterile facility or in case of for-cause inspections.

    3. Have a Written Procedure

    Having a written procedure that will be followed during a regulatory inspection, including one by FDA, will be of tremendous help for the responsible employees of the firm for a smooth and successful inspection.

    4. Assign an Inspection Preparedness Team

    An inspection preparedness team with an inspection coordinator should be assigned to ensure all relevant activities and documentation are tracked, completed, and evaluated in a timely manner. The inspection coordinator holds regular meetings with the aid of operation plans to ensure preparations for inspection are running smoothly and issues are resolved in a timely manner.

    5. Documents to Keep Ready

    There are some documents commonly requested by the FDA investigators and keeping them ready can help the firm focus on other requested items during the inspection. Some of the commonly requested documents include, but are not limited to the following:

    • Initial overview presentation of the firm
    • Site Master File
    • Organization Chart up to Operator or Analyst level
    • SOP Master Index
    • Training procedure
    • Recall procedure
    • Batch numbering procedure
    • List of deviations, change controls, OOS, complaints investigations and CAPAs since the last inspection
    • Responses and CAPAs to prior FDA 483 Observations

    It is almost certain that you will be asked about other procedures as well. Decide who makes and who keeps copies of FDA requested documents. Screen records before giving them to the FDA but do not delay delivery. If unavoidable, explain the reason for any delay. Only provide documents that FDA requests. Remove post-it notes, hand-written comments or extra pages. Make two copies of each document provided to the FDA—one for the FDA and one for the site. Mark each set as “Copy” and “Confidential.” Guard originals and keep originals nearby until they can be filed and stored properly. Have a system to trace and recover documents and to ensure their return to the originating department.

    6. Keeping the Facility Ready

    It is important that you always keep your facility in a presentable form to an FDA investigator. Inform employees of the upcoming or ongoing inspection. Unauthorized pages or copies of procedures on desks or walls should be avoided. Label everything—ensure equipment and signs are displayed properly, identify manufacturing equipment, and calibration stickers must be current. Remove items or equipment that are out of service; otherwise, ensure an “Out of Service” sign is displayed. Repair damaged areas—ensure there are no cracks on the walls or floors; paint damaged areas. Dispose of as much Hold and Reject material as possible. Review status labeling in all storage areas.

    7. During the Inspection

    A brief introductory presentation showing the history of the company, compliance history, organizational chart, headcount, hours of operation, list of products, list of major equipment and software and facility layout can be made on the first day. This will help the investigator get familiar with your site before walking into the facility for inspection. Also, the inspection will include a facility tour which will most likely happen on the first day of the inspection.

    Present the FDA investigator’s question to site personnel in the “Backroom” and prepare responses before meeting with the FDA investigator. Ask for clarification if a question or request is vague. Listen carefully to what you are asked and respond directly to the question. Make sure you understand the question before you answer. Answer questions accurately and succinctly and do not elaborate or guess. Do not delay, deny, limit, or refuse an FDA inspection as it may lead to further actions by the agency as they are considered prohibited behaviors and may cause a drug to be considered adulterated as described in the FDA guidance document, titled, Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection.2

    8. FDA Documents Request

    It is not uncommon to receive a document request from the FDA investigator, particularly before an international inspection. If you receive such a request and you have doubts, ask for clarification. Some investigators ask the firm to have all the requested documents ready on the first day of the inspection. Preference among FDA investigators in collecting documents varies to a large extent, some preferring electronic documents, and some preferring hard copies, and others preferring both formats. It is common for FDA investigators to request electronic documents in a CD, DVD or USB format.

    9. Documenting the Investigator’s Request

    It is a good practice to document all the requests made by an investigator during the inspection. Document Room staff roles and responsibilities should include:

    • Recording, prioritizing and tracking of document requests
    • Retrieving and reviewing documents
    • Sorting documents
    • Staging documents for investigator review
    • Esuring that complete records and copies are kept of all documentation provided to the investigators
    • Tacking all documents entering and leaving the inspection room

    10. Backroom Support

    Although it might seem like all the important activities occur in the front room, the effectiveness of the backroom management is the key deciding factor in most successful inspections. In fact, the backroom is also called as the “war room.” A well-prepared and well-organized backroom is one of the most crucial elements of FDA inspection management, enabling your firm to act quickly and appropriately to any FDA investigator’s request. Qualified consultants can provide onsite support during FDA inspections, assist in backroom management, and provide inspection preparedness training.

    11. General Conduct During FDA Inspection

    Here are some general recommendations for the employees to follow during the inspection:

    •  Escort the FDA investigator to the conference room upon arrival
    •  The senior most person on site to receive Form FDA 482 (only for domestic) and verify accuracy of FDA 482 contents; will also receive FDA 483 at the closing of the inspection, if issued
    •  Explain site rules including safety rules
    •  Make sure site personnel are available when FDA investigator arrives daily
    •  At start of the day, ask for the agenda for that day
    •  Request daily wrap-up for discussing any potential FDA concerns
    •  Periodically ask investigator if he/she has received the information requested
    •  Avoid unrelated discussions in the room with FDA investigator as this may distract the FDA personnel
    •  FDA concern is valid, acknowledge and commit to correct in a timely manner
    •  Provide evidence of corrections made during the inspection
    •  It is proper to provide information on corrective actions to FDA 483, if appropriate

    12. Daily Wrap-up Meeting

    According to the FDA’s Investigations Operations Manual (IOM), “Investigators and analysts should make every reasonable effort to discuss all observations with the management of the establishment as they are observed, daily, to minimize surprises, errors, and misunderstandings when the FDA 483 is issued. This discussion should include those observations, which may be written on the FDA 483 and those that will only be discussed with management during the closeout meeting. Industry may use this opportunity to ask questions about the observations, request clarification, and inform the inspection team what corrections have been or will be made during the inspection process. Investigators are encouraged to verify the establishment’s completed corrective actions as long as the verification does not unreasonably extend the duration of the inspection.”1 As the IOM recommends FDA investigators are generally not averse to conducting a daily wrap-up meeting. The firm should ask for one.

    13. Close-out Meeting

    Make sure that the most senior person available at the facility is sitting at the table during the closeout meeting with the investigators. This is important in demonstrating that your firm is taking the inspection findings seriously and interested in learning the inspection outcome to address the deficiencies. The close-out may include sample collections, affidavits (domestic) and issuance of Form FDA-483 Inspectional Observations. In addition to the Form FDA 483, the investigator may also verbally discuss minor deficiencies with firm management and may include the discussion items under the “General Discussion with Management” heading in the Establishment Inspection Report (EIR).

    14. Response to the FDA Form 483

    The FDA will generally allow firms 15 business days to provide a response to the FDA 483 observations. If FDA receives a response to FDA 483 observations within 15 business days after the FDA 483 was issued, they will conduct a detailed review of the response before determining whether to take any regulatory actions.

    Form a cross-functional committee immediately to formulate responses. Responses should be as specific as possible. If there is more than one part to the observation, respond to each part. The response to the FDA 483 should include corrections to any inaccurate statements in the FDA 483. Demonstrate, if possible, how and why the existing systems in question are in conformance with GLP/GMP and, therefore, not deficient. Provide a corrective action in the response and a realistic timetable for the completion for the corrective actions.

    15. Inspection Outcome

    The FDA inspection outcome of a firm can have substantial impact on the business operations of the company. The FDA inspections may be classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI), in the increasing severity order depending on the outcome. When no Form FDA 483 ‘Inspectional Observations’ is issued it is classified as NAI. When a Form FDA 483 is issued it may be classified as VAI or OAI depending on the significance of the deficiencies. OAI classifications may lead to further regulatory actions like, Regulatory Meetings, Untitled Letters, Warning Letters, Import Alerts, Injunctions and Seizures. Irrespective of the classification each inspection will have an Establishment Inspection Report (EIR) written by the FDA investigator and a copy will be sent to the firm as per FMD-145 (Field Management Directive). The investigators are also expected to report significant discussions with firm management in the EIR.

    References

    1. FDA, 2023 Investigations Operations Manual (IOM), https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/investigations-operations-manual, web accessed on March 27, 2023.
    2. FDA, Guidance for Industry: Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection, October 2014, https://www.fda.gov/media/86328/download.



    Tamil Arasu, Ph.D., is a Principal Consultant at Lachman Consultant Services, Inc. who brings a unique background of both U.S. FDA and pharmaceutical industry experience to Lachman clients. He is an expert in cGMP and ICH guidelines and had conducted FDA pharmaceutical inspections as lead investigator in more than 10 countries prior to joining Lachman Consultants. His expertise includes APIs, sterile and non-sterile pharmaceuticals involving complex formulations, and biological products. He is co-author on more than 20 peer-reviewed scientific research articles and co-inventor on multiple U.S. patents.
      Loading, Please Wait..
      Trending
      • SpectronRx, RLS Partner To Boost Radiopharmaceutical Pipeline And Supply Chain
      • Samsung Biologics Accelerates Timeline Of New Fifth Plant
      • Biopharma Layoffs In 1Q23
      • Veeva Business Consulting Expands With New R&D Services
      • CRO Industry Trends & Challenges
      Breaking News
      • EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
      • RK Pharma to Receive $200M Investment from PAG
      • Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
      • TMC Expands Executive Team
      • Peli BioThermal Opens Cold Chain Network Station in Southern California
      View Breaking News >
      CURRENT ISSUE

      May 2023

      • New Modalities Hog the Limelight
      • Cell and Gene Therapy is Coming of Age
      • Demand Surges for Cell and Gene Therapy Contract Manufacturing
      • Embracing a New Reality
      • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
      • Single-Use Technologies Enable Biologic Scaling
      • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
      • FTEs in Drug Discovery
      • Digital Transformation in Pharma
      • What is a Manufacturing Ecosystem and Why are They Growing?
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Sempera Organics and Alkemist Labs Announce Partnership for Mushroom Testing
      Nektium Expands International Distribution Network for Botanical Extracts
      Kemin Receives Positive EFSA Opinion for BetaVia Pure, its Beta-Glucan Ingredient
      Coatings World

      Latest Breaking News From Coatings World

      PPG’s New Paint for a New Start Initiative to Beautify Schools Worldwide with Colorful Makeovers
      Powder Technology, Inc. Announces New Electrical Coating
      Michelman Chosen as Inaugural Recipient of Innovation Research Interchange (IRI) Excellence Award
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Cue Health Nabs FDA's First De Novo Nod for an At-Home COVID Test
      ISO 13485:2016 Certification Granted to Boston BioProducts
      Paul Colvin Joins Ora Inc. as Chief Operating Officer
      Contract Pharma

      Latest Breaking News From Contract Pharma

      EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
      RK Pharma to Receive $200M Investment from PAG
      Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Estée Lauder Announces Second Edition of Beauty&You Brand Incubator Program
      GetHarley Raises $52 Million in Latest Funding Round
      Refillable Skincare Products Face Hurdles Despite Growing Sustainability Awareness
      Happi

      Latest Breaking News From Happi

      Carrière Frères Introduces Candle Refills as New Sustainability Initiative
      Gen Z Entrepreneur Introduces The Ashley Marie Collection for 4C Hair Types
      The Estée Lauder Companies Expands Beauty&You Competition for Indian Beauty Brands
      Ink World

      Latest Breaking News From Ink World

      Siegwerk’s Center of Excellence in France Receives Facelift
      Epson announces MakeTheSwitch Campaign
      Pigments Market to Reach $26,598 Million by 2022: AMR
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Mark Andy reports successful Low Migration Workshop
      Ryback and Ryback Consulting launches Machinery division
      TLMI launches 2023 award programs
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      The Honest Company to Exit Europe, Asia
      TechnoPlants to Exhibit at ITMA
      Andritz Buys 100% Stake in Dan-Web
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Orthobiologics Market to Top $10.3 Billion by 2030
      Artelon Granted U.S. FDA 510(k) Clearance for FlexBand, FlexPatch & FlexBand Plus
      Synergy Spine Solutions Completes Enrollment in IDE Clinical Trial
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      ASSA ABLOY Receives Clearance from Mexico for HHI Acquisition
      Christoph Ostermann Named Chairman of Heliatek‘s Advisory Board
      Flexible and Printed Electronics Represented at productronica 2023

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login